Avian Flu Scan for Dec 10, 2015

News brief
Topics
Avian Influenza (Bird Flu)
Pandemic Influenza

H7N9 prime-boost vaccine strategy shows promise in early trial

As part of an ongoing effort to weigh different vaccine strategies against H7N9 avian influenza, researchers today reported results from a small clinical trial that showed promise for a prime-boost strategy.

A research team led by the National Institute of Allergy and Infectious Diseases (NIAID) reported the findings in the Journal of Infectious Diseases.

In a press release today, the NIAID said several H7N9 vaccines using inactivated viruses appear to be safe and able to generate an immune response. It added, however, that multiple doses or adjuvanted vaccine would be needed in practical use.

In the clinical trial published today, the live attenuated influenza virus (LAIV) inhaled primer vaccine was given first, followed 2 weeks later by an inactivated virus vaccine designed to prompt a more robust immune response. The study included 65 adults in two age groups: 18 to 49 and 50 to 70. The NIAID said the study is the first to test the LAIV in the older age-group, which is known to be at greater risk for severe H7N9 infection.

Volunteers received one or two doses of the LAIV vaccine produced by MedImmune, followed by a dose of inactivated H7N9 vaccine made by Sanofi. Serum antibody responses were detected in three volunteers. Strong serum responses were seen after the booster dose. Both vaccines were well tolerated.

The NIAID said it's not known if the LAIV vaccine alone would have been protective without the booster, but it added that studies on other LAIV candidates generated long-lasting immunity that is rapidly recalled with an inactivated vaccine dose.

Three days ago a research team from Russia and the World Health Organization reported promising phase 1 findings for a H7N9 LAIV candidate. Subjects in that study received two doses, and the vaccine was tested in 29 adults ages 18 to 49. There were 10 volunteers in the placebo group.
Dec 10 J Infect Dis abstract
Dec 10 NIAID press release
Dec 8 CIDRAP News scan "Phase 1 trial shows good safety, immune response for H7N9 vaccine"

In related developments, another H7N9 case was detected in China, but few details are available.

The illness was hinted at in a surveillance report for November released by China's National Health and Family Planning Commission, translated and posted today by FluTrackers, an infectious disease news message board. The case is the sixth in China's early part of its fourth wave of H7N9 illnesses and would boost the overall global total to 691, according to a case list kept by FluTrackers.
Dec 10 FluTrackers thread
FluTrackers H7N9 case list

 

France confirms 2 new avian flu outbreaks, 1 involving H5N9

France has reported two new outbreaks of highly pathogenic avian flu and a new affected district, bringing to 12 the number of recent outbreaks and to four the number of affected regions, Reuters reported today.

France's agriculture ministry said H5N2 has struck birds at an 8,300-duck farm in Gers region, which had not before experienced an outbreak. In addition, a strain never before seen in Europe—H5N9—caused its third outbreak in France, this time hitting a farm that houses more than 20,000 chickens, guinea fowl, and ducks in neighboring Landes region.

Seven of the 12 outbreaks have hit poultry in Dordogne, 3 in Landes, and 1 each in Haute-Vienne and Gers. All are in southwestern France. In addition to H5N2 and H5N9, the H5N1 strain has also caused poultry deaths and forced the culling of surviving birds.

France is Europe's largest agricultural producer, and the impact of the virus has come at a crucial time for the country's foie gras producers. Demand for the delicacy typically peaks during the year-end holiday season.

French officials have said that the strains detected so far have all been of European origin.
Dec 10 Reuters report

News Scan for Dec 10, 2015

News brief
Topics
West Nile
Dengue
Viral Hemorrhagic Fever

Arizona reports concurrent West Nile, St Louis encephalitis outbreak

Arizona residents are experiencing the first known outbreak of concurrent West Nile virus (WNV) and St. Louis encephalitis virus (SLEV) infections in the United States, and most cases involve neurologic disease, the Centers for Disease Control and Prevention (CDC) reported today in Morbidity and Mortality Weekly Report (MMWR).

The viruses, both flaviviruses, are carried by Culex mosquitoes.

As of Nov 24, 117 cases of flavivirus disease had been reported to the Arizona Department of Health Services, including 75 WNV, 19 SLEV, and 23 unspecified flavivirus disease cases. In addition, during the summer the Maricopa County Vector Control Division identified 60 pools of C tarsalis or C quinquefasciatus mosquitoes that tested positive for SLEV RNA by polymerase chain reaction, and 97 pools that tested positive for WNV RNA.

Among all cases, 103 (88%) occurred from July through September. Seventy-nine patients (68%) had neuroinvasive disease, such as meningitis, encephalitis, or acute flaccid paralysis, including 47 (63%) with WNV infection, 17 (89%) with SLEV infection, and 15 (65%) with unspecified flavivirus infection. Of the patients, 86 (74%) were hospitalized and 5 (4%) died.

Eight (53%) of the state's 15 counties reported cases, and 45 WNV cases (60%) and 18 SLEV cases (95%) were in Maricopa County, the CDC said.

The authors warn, "Because of the similarity in clinical presentation for WNV and SLEV disease cases, cross reactivity between WNV and SLEV antibodies, and the lack of availability of a commercial SLEV test, SLEV disease cases could be incorrectly diagnosed as WNV disease cases or remain undetected if clinicians only request WNV testing and no confirmatory testing is conducted."
Dec 11 MMWR report

 

Dengue vaccine approved for use in Mexico to make it world's first

Mexican authorities have approved Sanofi Pasteur's Dengvaxia, making it the first vaccine to be licensed in the world for preventing dengue, the company said yesterday in a news release.

Mexico's Federal Commission for the Protection against Sanitary Risks (COFEPRIS) approved the tetravalent vaccine against all four dengue virus serotypes in those 9 to 45 years of age who live in dengue-endemic areas.

Sanofi CEO Olivier Brandicourt, MD, said, "This is a historic milestone for our company, for the global public health community and, most importantly, for half the world's population who lives at risk of dengue."

The COFEPRIS approval is based on results from clinical trials involving more than 40,000 people in 15 countries, Sanofi said. Dengue-endemic areas of Mexico participated in all three trial phases.

In January phase 3 trial results showed 60% overall efficacy for the vaccine, and in July phase 2 and 3 results indicated that it might drop hospital risks in older children.
Dec 9 Sanofi news release
Jan 9 and Jul 27 CIDRAP News items on clinical trials

This week's top reads

  1. FDA significantly limits COVID-19 vaccine recommendations

    Critics said today’s announcement is more evidence of the current administration’s willingness to undermine public trust in vaccines.

    Stephanie Soucheray
    FDA building

  2. Woman dies of Creutzfeldt-Jakob almost 50 years after taking prion-contaminated growth hormone

    The patient, who presented with gait imbalance and tremors, wasn't diagnosed until she was in a coma, shortly before she died.

    Mary Van Beusekom
    Woman in hospital bed

  3. Meta-analysis: Zika-infected pregnant moms 4 times more likely to have babies with microcephaly

    Five of 22 studies noted that over 50% of newborns had microcephaly, and the same number of studies observed that over 5% had congenital Zika syndrome. 

    Mary Van Beusekom

  4. HHS expected to discontinue COVID vaccine recommendations for some groups

    When CDC advisers widened their recommendation in 2023, most members were swayed by data, including those for long COVID, showing that no group is at low risk for the virus.

    Lisa Schnirring

  5. WHO advisers say current strains OK for COVID vaccine production

    Current vaccine strains show high neutralization against the latest variants, but the LP.8.1 antigen may provide similar or moderately higher cross-reactive antibody response.

    Lisa Schnirring
    senior vaccination

  6. US measles outbreak grows to 1,024 cases

    Texas remains the country's hot spot, with 718 cases. 

    Chris Dall
    Doctor treating child with measles

  7. Moderna pulls licensing submission for combo flu-COVID vaccine

    Moderna's combination vaccine was intended for adults 50 and older. 

    Stephanie Soucheray

  8. Flu vaccine efficacy 41% overall and 26% in older adults, per 2023-24 estimates

    Estimated effectiveness was 68% against influenza B and 32% against type A.

    Mary Van Beusekom
    Flu shot going into arm

  9. Mpox activity escalates in Sierra Leone

    Responding to the surge is a major focus, partly to prevent the spread to other West African countries. 

    Lisa Schnirring
    mpox virus

  10. Testing ties Listeria outbreak to ready-to-eat sandwiches

    An earlier investigation hinted at hospital food as a source, but evidence didn't reveal a specific item.

    Lisa Schnirring

Our underwriters